Agilent Technologies (A) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.41 per share. This compares to earnings of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.55%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.25 per share when it actually produced earnings of $1.32, delivering a surprise of 5.60%.Over the last four qu ...

[Financial Highlights](index=1&type=section&id=Financial%20Highlights) Agilent reported solid Q4 and full fiscal year 2024 financial results, driven by strong execution and a new market-based strategy Q4 Fiscal Year 2024 Financial Highlights | Metric | Q4 2024 | Q4 2023 | Change | Core Change | | :--- | :--- | :--- | :--- | :--- | | Revenue | $1.70B | $1.69B | +0.8% | -0.3% | | GAAP Net Income | $351M | $475M | -26.1% | N/A | | GAAP EPS | $1.22 | $1.62 | -24.7% | N/A | | Non-GAAP Net Income | $418M | $404M | +3.5% | N/A | | Non-GAAP EPS | $1.46 | $1.38 | +5.8% | N/A | Full Fiscal Year 2024 Financial Highlights | Metric | FY 2024 | FY 2023 | Change | Core Change | | :--- | :--- | :--- | :--- | :--- | | Revenue | $6.51B | $6.83B | -4.7% | -4.7% | | GAAP Net Income | $1.289B | $1.240B | +4.0% | N/A | | GAAP EPS | $4.43 | $4.19 | +5.7% | N/A | | Non-GAAP Net Income | $1.539B | $1.609B | -4.3% | N/A | | Non-GAAP EPS | $5.29 | $5.44 | -2.8% | N/A | - **CEO Padraig McDonnell** stated that the team delivered solid Q4 results as markets continued to recover, emphasizing that the new market-based, customer-first strategy and organizational structure will position the company for more growth opportunities as the market improves[6](index=6&type=chunk) [Segment Performance](index=2&type=section&id=Segment%20Performance) Agilent CrossLab Group (ACG) showed consistent growth in Q4 and full fiscal year 2024, while other segments experienced declines Life Sciences and Applied Markets Group (LSAG) Performance | Period | Revenue | Reported Change | Core Change | Operating Margin | | :--- | :--- | :--- | :--- | :--- | | Q4 2024 | $833M | -1% | -1% | 28.0% | | FY 2024 | $3.22B | -8% | -8% | 27.3% | Diagnostics and Genomics Group (DGG) Performance | Period | Revenue | Reported Change | Core Change | Operating Margin | | :--- | :--- | :--- | :--- | :--- | | Q4 2024 | $442M | -1% | -3% | 21.2% | | FY 2024 | $1.65B | -6% | -6% | 19.4% | Agilent CrossLab Group (ACG) Performance | Period | Revenue | Reported Change | Core Change | Operating Margin | | :--- | :--- | :--- | :--- | :--- | | Q4 2024 | $426M | +5% | +5% | 32.6% | | FY 2024 | $1.64B | +5% | +5% | 31.9% | [Financial Outlook](index=1&type=section&id=Full%20Year%202025%20and%20First-Quarter%20Outlook) Agilent provided its fiscal year 2025 and first-quarter 2025 financial guidance, projecting modest revenue and EPS growth Fiscal Year 2025 Outlook | Metric | Guidance Range | | :--- | :--- | | Revenue | $6.790B - $6.870B | | Reported Revenue Growth | +4.3% to +5.5% | | Core Revenue Growth | +2.5% to +3.5% | | Non-GAAP EPS | $5.54 - $5.61 | First-Quarter Fiscal Year 2025 Outlook | Metric | Guidance Range | | :--- | :--- | | Revenue | $1.650B - $1.680B | | Reported Revenue Growth | -0.5% to +1.3% | | Core Revenue Growth | -2.0% to -0.2% | | Non-GAAP EPS | $1.25 - $1.28 | [Corporate Developments](index=3&type=section&id=Corporate%20Developments) Agilent announced a new organizational structure as part of its transformation to become more agile and customer-centric - The company announced a new organizational structure to become nimbler and more customer-centric[15](index=15&type=chunk) - More information about the company's evolved market-focused strategy and transformation will be shared at its Investor Day in New York City on Dec. 17, 2024[15](index=15&type=chunk) - Management will host a conference call for investors to discuss Q4 2024 financial results, with a replay available on the company's website for 90 days[14](index=14&type=chunk) [Consolidated Financial Statements (Preliminary & Unaudited)](index=5&type=section&id=Consolidated%20Financial%20Statements) Preliminary financial statements detail the company's balance sheet, income, and cash flow, alongside reconciliations for non-GAAP measures and core revenue [Condensed Consolidated Statement of Operations](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENT%20OF%20OPERATIONS) The statement of operations details fiscal year 2024 revenue, income from operations, and GAAP net income, showing a slight increase in profitability despite lower revenue Fiscal Year Ended October 31 (In millions, except per share data) | Account | 2024 | 2023 | | :--- | :--- | :--- | | Net revenue | $6,510 | $6,833 | | Income from operations | $1,488 | $1,350 | | Net income | $1,289 | $1,240 | | Diluted EPS | $4.43 | $4.19 | [Condensed Consolidated Balance Sheet](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEET) The balance sheet shows an increase in total assets and liabilities as of October 31, 2024, with stable stockholders' equity Balance Sheet Highlights as of October 31 (In millions) | Account | 2024 | 2023 | | :--- | :--- | :--- | | Total current assets | $3,959 | $4,186 | | Total assets | $11,846 | $10,763 | | Total current liabilities | $1,895 | $1,603 | | Long-term debt | $3,345 | $2,735 | | Total liabilities | $5,948 | $4,918 | | Total stockholders' equity | $5,898 | $5,845 | [Condensed Consolidated Statement of Cash Flows](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENT%20OF%20CASH%20FLOWS) Cash flow statement indicates strong operating cash flow, increased investing activities due to acquisitions, and significant cash used in financing for repurchases and dividends Cash Flow Summary for Fiscal Year Ended October 31 (In millions) | Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net cash provided by operating activities | $1,751 | $1,772 | | Net cash used in investing activities | $(1,258) | $(310) | | Net cash used in financing activities | $(752) | $(930) | | Net (decrease) in cash | $(261) | $537 | | Cash at end of period | $1,332 | $1,593 | [Non-GAAP Reconciliations](index=10&type=section&id=NON-GAAP%20NET%20INCOME%20AND%20DILUTED%20EPS%20RECONCILIATIONS) Non-GAAP reconciliations provide adjusted financial metrics, excluding specific items like intangible amortization and restructuring costs, to offer a clearer view of operational performance FY 2024 GAAP to Non-GAAP Reconciliation (In millions, except EPS) | Description | Net Income | Diluted EPS | | :--- | :--- | :--- | | **GAAP** | **$1,289** | **$4.43** | | Intangible amortization | $102 | $0.35 | | Restructuring and other related costs | $76 | $0.26 | | Other adjustments (net) | $72 | $0.25 | | **Non-GAAP** | **$1,539** | **$5.29** | - Non-GAAP adjustments primarily exclude charges for restructuring, asset impairments, intangible amortization, transformational initiatives, and acquisition/integration costs[19](index=19&type=chunk)[34](index=34&type=chunk) [Segment Revenue Reconciliation (Core)](index=14&type=section&id=RECONCILIATION%20OF%20REVENUE%20BY%20SEGMENT%20(CORE)) Segment revenue reconciliation adjusts reported revenue for currency and M&A impacts to present core growth, highlighting underlying business performance Q4 2024 Revenue Growth: Reported vs. Core | Segment | Reported Growth | Core Growth | | :--- | :--- | :--- | | LSAG | -1% | -1% | | DGG | -1% | -3% | | ACG | +5% | +5% | | **Agilent Total** | **+1%** | **0%** | FY 2024 Revenue Growth: Reported vs. Core | Segment | Reported Growth | Core Growth | | :--- | :--- | :--- | | LSAG | -8% | -8% | | DGG | -6% | -6% | | ACG | +5% | +5% | | **Agilent Total** | **-5%** | **-5%** |

Agilent Technologies, Inc. A will release earnings results for the fourth quarter, after the closing bell on Monday, Nov. 25.Analysts expect Agilent to report quarterly earnings at $1.41 per share. That's up from $1.38 per share a year ago. The Santa Clara, California-based company projects to report quarterly revenue of $1.67 billion, compared to $1.69 billion a year earlier, according to data from Benzinga Pro.On Nov. 20, Agilent raised its quarterly dividend to 24.8 cents per share of common stock, a 5% ...

Agilent Technologies (A) is set to report fourth-quarter fiscal 2024 results on Nov. 25.For the fiscal fourth quarter, the company expects revenues of $1.641-$1.691 billion, suggesting a decline of 2.8-0.2% on a reported basis and 1.9-1.1% on a core basis from the year-ago quarter’s actuals.The Zacks Consensus Estimate for revenues is pegged at $1.67 billion, indicating a marginal decline of 0.86% from the year-ago quarter’s reported figure.Agilent’s non-GAAP earnings are expected to be $1.38-$1.42 per shar ...

Earnings Report - Agilent Technologies, Inc. is set to release its fourth-quarter earnings results on November 25, with analysts expecting earnings of $1.41 per share, an increase from $1.38 per share in the same period last year [1] - The company is projected to report quarterly revenue of $1.67 billion, slightly down from $1.69 billion a year earlier [1] Analyst Ratings - Evercore ISI Group analyst Vijay Kumar has maintained an In-Line rating for Agilent and raised the price target from $135 to $145 [2] - The company currently offers an annual dividend yield of 0.75%, translating to a quarterly dividend of 24.8 cents per share [2] Dividend Calculations - To achieve a monthly dividend income of $500, an investor would need to own approximately 6,048 shares of Agilent, equating to a total investment of about $798,699 [3] - For a more conservative monthly income goal of $100, an investor would need to hold 1,210 shares, requiring an investment of around $159,793 [3] Stock Performance - Shares of Agilent increased by 2.7%, closing at $132.06 on Thursday [6]

Agilent Technologies Inc (NYSE:A) is scheduled to release fourth-quarter financial results after the close on Monday, Nov. 25. Analysts expect the medical research name to report earnings of $1.41 per share -- a 2.2% year-over-year increase -- on revenue of $1.67 billion.Looking back on its past eight post-earnings performances, A's history of next-day returns are split, with four positive and four negative. The equity averaged a move of 5.3%, regardless of direction in the last two years, and the options p ...

In its upcoming report, Agilent Technologies (A) is predicted by Wall Street analysts to post quarterly earnings of $1.41 per share, reflecting an increase of 2.2% compared to the same period last year. Revenues are forecasted to be $1.67 billion, representing a year-over-year decrease of 0.9%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this time ...

Agilent Technologies (A) boosts its LSAG segment with the launch of the Agilent InfinityLab Liquid Chromatography (LC) Series portfolio, comprising the 1290 Infinity III LC, 1260 Infinity III Prime LC and 1260 Infinity III LC systems.The new Agilent InfinityLab Assist Technology is being used for the first time in these High Performance Liquid Chromatography systems, providing enhanced system assistance.These systems have a significant impact on task automation, connectivity, predictive feedback and error r ...

Core Insights - Agilent Technologies reported Q3 fiscal 2024 earnings of $1.32 per share, exceeding estimates by 5.6%, but down 8% year-over-year [2] - Revenues reached $1.58 billion, surpassing the consensus estimate of $1.56 billion, but declined 5.6% year-over-year [2] - The company faced broad-based weakness across several markets, including Pharma, Food, Chemical, and Academic sectors, with weak momentum in China [2] Financial Performance - Life Sciences & Applied Markets Group (LSAG) generated $782 million, down 8% year-over-year, missing the consensus estimate of $849 million [3] - Agilent Cross Lab Group (ACG) revenues were $411 million, exceeding the consensus of $385 million, with a 4% year-over-year increase [3] - Diagnostics and Genomics Group (DGG) revenues decreased 9% year-over-year to $385 million, beating the consensus of $332 million [4] Operating Results - Gross margin for LSAG expanded by 10 basis points to 60.2%, while ACG's gross margin increased by 120 basis points to 52.1% [5] - DGG's gross margin contracted by 170 basis points to 51.8% [5] - Operating margin for Q3 was 21.1%, significantly up from 7.9% in the prior year [5][6] Balance Sheet - As of July 31, 2024, cash and cash equivalents were $1.78 billion, up from $1.67 billion in April 2024 [7] - Accounts receivables were $1.23 billion, slightly down from $1.25 billion in the previous quarter [7] - Long-term debt remained stable at $2.137 billion [7] Guidance - For Q4 fiscal 2024, management expects revenues between $1.641 billion and $1.691 billion, indicating a potential decline of 2.8% to an increase of 0.2% year-over-year [8] - Fiscal 2024 revenue guidance revised to $6.45-$6.50 billion, reflecting a decline of 5.6-4.9% year-over-year [8] - Non-GAAP earnings per share guidance for fiscal 2024 adjusted to $5.21-$5.25 [8] Market Sentiment - Recent estimates for Agilent have been trending downward, indicating a shift in market sentiment [9] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [11]

Agilent Technologies Inc. NYSE: A is a diversified global leader in the life sciences, diagnostics, and applied chemical markets. The company provides equipment systems, instruments, software and services that enable researchers and scientists to make breakthroughs in the medical sector and various fields. While its many segments are experiencing pullbacks in the end market, its top growth segment is being driven by solutions to address polyfluoroalkyl substances (PFAS), otherwise known as forever chemicals ...